Prediction of immune subtypes and overall survival in lung squamous cell carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Conti L, Gatt S. Squamous-cell carcinoma of the lung. N Engl J Med. 2018;379(11):e17.
   PubMed Web of Science ®Google Scholar
• Ruiz-Cordero R, Devine WP. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin. 2020;13(1):17–33.
   PubMedGoogle Scholar
• Rizvi NA, Hellmann MD, Brahmer JR, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(25):2969–2979.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Diamandis EP. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 2008;5(10):588–599.
   PubMedGoogle Scholar
• Wong-Rolle A, Wei HK, Zhao C, et al. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell. 2021;12(5):426–435.
   PubMed Web of Science ®Google Scholar
• Ribeiro IP, Melo JB, Carreira IM. Cytogenetics and cytogenomics evaluation in cancer. IJMS. 2019;20(19):4711.
   Google Scholar
• Laplane L, Duluc D, Bikfalvi A, et al. Beyond the tumour microenvironment. Int J Cancer. 2019;145(10):2611–2618.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhang Q, Yu C, et al. Immune cell infiltration-based signature for prognosis and immunogenomic analysis in breast cancer. Brief Bioinform. 2021;22(2):2020–2031.
   PubMed Web of Science ®Google Scholar
• Shen S, Wang G, Zhang R, et al. Development and validation of an immune gene-set based prognostic signature in ovarian cancer. EBioMedicine. 2019;40:318–326.
   PubMed Web of Science ®Google Scholar
• Chen H, Luo J, Guo J. Development and validation of a five-immune gene prognostic risk model in colon cancer. BMC Cancer. 2020;20(1):395.
   PubMed Web of Science ®Google Scholar
• Lung microbiota promote lung cancer. Cancer Discov. 2019;9:458.
   Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Qu Y, Cheng B, Shao N, et al. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma. Aging. 2020;12(6):4757–4777.
   PubMedGoogle Scholar
• Le T, Aronow RA, Kirshtein A, et al. A review of digital cytometry methods: estimating the relative abundance of cell types in a bulk of cells. Brief Bioinformat. 2021;22(4).
   Web of Science ®Google Scholar
• Fan T, Lu Z, Liu Y, et al. A novel immune-related seventeen-gene signature for predicting early stage lung squamous cell carcinoma prognosis. Front Immunol. 2021;12:665407.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang J, Yuan C, et al. Establishment of the prognostic index of lung squamous cell carcinoma based on immunogenomic landscape analysis. Cancer Cell Int. 2020;20:330.
   PubMed Web of Science ®Google Scholar
• Zhao K, Yang H, Kang H, et al. Identification of key genes in thyroid cancer microenvironment. Med Sci Monit. 2019;25:9602–9608.
   PubMed Web of Science ®Google Scholar
• Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
   PubMed Web of Science ®Google Scholar
• Agesen TH, Sveen A, Merok MA, et al. ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut. 2012;61(11):1560–1567.
   PubMed Web of Science ®Google Scholar
• Zhao S, Liu Q, Li J, et al. Construction and validation of prognostic regulation network based on RNA-binding protein genes in lung squamous cell carcinoma. DNA Cell Biol. 2021;40(12):1563–1583.
   PubMed Web of Science ®Google Scholar
• Bruni D, Angell HK, Galon J. The immune contexture and immunoscore in cancer prognosis and therapeutic efficacy. Nat Rev Cancer. 2020;20(11):662–680.
   PubMed Web of Science ®Google Scholar
• van der Burg SH. Correlates of immune and clinical activity of novel cancer vaccines. Semin Immunol. 2018;39:119–136.
   PubMed Web of Science ®Google Scholar
• Li B, Cui Y, Diehn M, et al. Development and validation of an individualized immune prognostic signature in early-stage nonsquamous non-small cell lung cancer. JAMA Oncol. 2017;3(11):1529–1537.
   PubMed Web of Science ®Google Scholar
• Anichini A. Progress in understanding complexity and determinants of immune-related prognostic subsets in primary melanoma. Cancer Res. 2019;79(10):2457–2459.
   PubMed Web of Science ®Google Scholar
• Wei C, Liang Q, Li X, et al. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer. J Cell Biochem. 2019;120(9):14916–14927.
   PubMed Web of Science ®Google Scholar
• Roelands J, Kuppen PJK. Immunogenomic classification of colorectal cancer and therapeutic implications. 2017;18.
   Google Scholar
• Lazăr DC, Avram MF, Romoșan I, et al. Prognostic significance of tumor immune microenvironment and immunotherapy: novel insights and future perspectives in gastric cancer. World J Gastroenterol. 2018;24(32):3583–3616.
   PubMed Web of Science ®Google Scholar
• Lee JC, Ahn S, Cho IK, et al. Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis. BMJ Open. 2018;8(4):e017249.
   PubMed Web of Science ®Google Scholar
• Antonelli G, Vanella G, Orlando D, et al. Recurrence and cancer-specific mortality after endoscopic resection of low- and high-risk pT1 colorectal cancers: a meta-analysis. Gastrointest Endosc. 2019;90(4):559–569.e3.
   PubMed Web of Science ®Google Scholar
• Liu P, Xu H, Shi Y, et al. Potential molecular mechanisms of plantain in the treatment of gout and hyperuricemia based on network pharmacology. Evid Based Complement Alternat Med. 2020;2020:3023127.
   PubMedGoogle Scholar